Pro-Dex (NASDAQ:PDEX) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Pro-Dex, Inc. (NASDAQ:PDEX) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $38.44 and traded as high as $39.38. Pro-Dex shares last traded at $38.45, with a volume of 21,858 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Pro-Dex in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Pro-Dex has an average rating of “Moderate Buy” and a consensus target price of $56.00.

Pro-Dex Price Performance

The firm has a market cap of $123.42 million, a price-to-earnings ratio of 11.31 and a beta of -0.05. The company’s fifty day moving average is $40.55 and its 200 day moving average is $38.44. The company has a quick ratio of 2.25, a current ratio of 4.03 and a debt-to-equity ratio of 0.19.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, January 29th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.07. Pro-Dex had a net margin of 15.73% and a return on equity of 22.53%. The firm had revenue of $18.66 million for the quarter, compared to analyst estimates of $17.30 million. On average, equities research analysts predict that Pro-Dex, Inc. will post 2 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. D.A. Davidson & CO. boosted its holdings in shares of Pro-Dex by 152.3% in the 3rd quarter. D.A. Davidson & CO. now owns 26,073 shares of the medical instruments supplier’s stock valued at $883,000 after buying an additional 15,738 shares during the last quarter. CreativeOne Wealth LLC acquired a new position in Pro-Dex during the second quarter worth $297,000. Hillsdale Investment Management Inc. bought a new stake in Pro-Dex during the second quarter worth $157,000. Ritholtz Wealth Management lifted its stake in Pro-Dex by 32.4% in the second quarter. Ritholtz Wealth Management now owns 21,102 shares of the medical instruments supplier’s stock valued at $921,000 after acquiring an additional 5,158 shares during the last quarter. Finally, Morgan Dempsey Capital Management LLC acquired a new stake in Pro-Dex in the second quarter valued at $179,000. 15.28% of the stock is owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.